[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2009124103A3 - Combination therapies comprising par1 antagonists with par4 antagonists - Google Patents

Combination therapies comprising par1 antagonists with par4 antagonists Download PDF

Info

Publication number
WO2009124103A3
WO2009124103A3 PCT/US2009/039070 US2009039070W WO2009124103A3 WO 2009124103 A3 WO2009124103 A3 WO 2009124103A3 US 2009039070 W US2009039070 W US 2009039070W WO 2009124103 A3 WO2009124103 A3 WO 2009124103A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonists
par1
par4
combination therapies
optionally
Prior art date
Application number
PCT/US2009/039070
Other languages
French (fr)
Other versions
WO2009124103A2 (en
Inventor
Yan Xia
Samuel Chackalamannil
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of WO2009124103A2 publication Critical patent/WO2009124103A2/en
Publication of WO2009124103A3 publication Critical patent/WO2009124103A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to a pharmaceutical composition comprising an effective amount of at least one PAR1 antagonist, at least one PAR4 antagonist, optionally, an effective amount of at least one cardiovascular agent, and, optionally, a pharmaceutically acceptable carrier. The present invention also provides for the use of theses pharmaceutical compositions to treat various diseases associated with thrombosis.
PCT/US2009/039070 2008-04-02 2009-04-01 Combination therapies comprising par1 antagonists with par4 antagonists WO2009124103A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4177008P 2008-04-02 2008-04-02
US61/041,770 2008-04-02

Publications (2)

Publication Number Publication Date
WO2009124103A2 WO2009124103A2 (en) 2009-10-08
WO2009124103A3 true WO2009124103A3 (en) 2010-01-14

Family

ID=40844808

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/039070 WO2009124103A2 (en) 2008-04-02 2009-04-01 Combination therapies comprising par1 antagonists with par4 antagonists

Country Status (1)

Country Link
WO (1) WO2009124103A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527535T3 (en) * 2010-04-16 2015-01-26 Sanofi Pyridyl-vinyl-pyrazolo-quinolines as PAR1 inhibitors
PL2558465T3 (en) 2010-04-16 2015-05-29 Sanofi Sa Tricyclic pyridyl-vinyl-pyroles as par1 inhibitors
US20160095897A1 (en) 2013-04-22 2016-04-07 Institut National De La Recherche Agronomique Par-4 antagonists for use in the treatment or prevention of influenza virus type a infections
TW201738221A (en) * 2016-04-22 2017-11-01 Jiangsu Tasly Diyi Pharmaceutical Co Ltd New himbacine analogue and uses thereof in medicines
SG11202110742TA (en) 2019-04-02 2021-10-28 Aligos Therapeutics Inc Compounds targeting prmt5
CN110407819B (en) * 2019-08-02 2020-06-26 牡丹江医学院 Thrombin receptor antagonists as a prophylactic for surgical complications

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089428A1 (en) * 2002-04-16 2003-10-30 Schering Corporation Tricyclic thrombin receptor antagonists
WO2007075964A2 (en) * 2005-12-22 2007-07-05 Schering Corporation Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
WO2007117621A1 (en) * 2006-04-06 2007-10-18 Schering Corporation Use of combination preparations containing thrombin receptor antagonists for treating cardiovascular disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089428A1 (en) * 2002-04-16 2003-10-30 Schering Corporation Tricyclic thrombin receptor antagonists
WO2007075964A2 (en) * 2005-12-22 2007-07-05 Schering Corporation Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
WO2007117621A1 (en) * 2006-04-06 2007-10-18 Schering Corporation Use of combination preparations containing thrombin receptor antagonists for treating cardiovascular disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LEGER A J ET AL: "Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis", CIRCULATION 200603 US, vol. 113, no. 9, March 2006 (2006-03-01), pages 1244 - 1254, XP002537535, ISSN: 0009-7322 *
LEGER A J ET AL: "Protease-activated receptors in cardiovascular diseases", CIRCULATION 200609 US, vol. 114, no. 10, September 2006 (2006-09-01), pages 1070 - 1077, XP002537536, ISSN: 0009-7322 *
WU ET AL: "Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER BV, NL, vol. 546, no. 1-3, 28 September 2006 (2006-09-28), pages 142 - 147, XP005646239, ISSN: 0014-2999 *

Also Published As

Publication number Publication date
WO2009124103A2 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2010039977A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2010054113A3 (en) Cycloalkane[b]azaindole antagonists of prostaglandin d2 receptors
WO2010003127A3 (en) Antagonists of prostaglandin d2 receptors
WO2009145989A3 (en) Aminoalkylphenyl antagonists of prostaglandin d2 receptors
WO2010057118A3 (en) Heterocyclic antagonists of prostaglandin d2 receptors
WO2012032209A3 (en) Pharmaceutical composition for the treatment of dry eye
PH12015501737A1 (en) Androgen receptor modulators and uses thereof
WO2010037054A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2009100441A3 (en) Depot formulations
WO2009140642A3 (en) Tricyclic antagonists of prostaglandin d2 receptors
MY154909A (en) Novel thiophene derivatives
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
MY164730A (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2010085820A3 (en) Tricyclic compounds as antagonists of prostaglandin d2 receptors
IL207976A0 (en) Novel 02x7r antagonists and their use
WO2009124103A3 (en) Combination therapies comprising par1 antagonists with par4 antagonists
WO2011143457A3 (en) Compositions and methods for treating or preventing atrial fibrillation
EP2438923A4 (en) Composition for preventing or treating obesity-related diseases mediated by the activation of ampk and including 2,5-bis-aryl-3,4-dimethyltetrahydrofuran lignans as active ingredients
NZ714288A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
WO2010033167A3 (en) Anti-thrombin aptamer formulations and methods for use
MX2009011744A (en) Unit dose formulations and methods of treating and preventing thrombosis with thromboxane receptor antagonists.
WO2009156680A3 (en) Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders
WO2009102707A3 (en) Substituted oxazaphosphorines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09727836

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09727836

Country of ref document: EP

Kind code of ref document: A2